U.S., April 5 -- ClinicalTrials.gov registry received information related to the study (NCT06911827) titled 'A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients' on March 28.
Brief Summary: The goal of this clinical trial is to evaluate the safety and efficacy of QLP2117 in combination with QL2107 in Advanced Solid Tumor Patients.
Study Start Date: April, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: QLP2117
Specified dose on specified days
DRUG: QL2107
Specified dose on specified days
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qilu Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....